PE20240144A1 - Inhibidores de mk2 y usos de estos - Google Patents
Inhibidores de mk2 y usos de estosInfo
- Publication number
- PE20240144A1 PE20240144A1 PE2023002765A PE2023002765A PE20240144A1 PE 20240144 A1 PE20240144 A1 PE 20240144A1 PE 2023002765 A PE2023002765 A PE 2023002765A PE 2023002765 A PE2023002765 A PE 2023002765A PE 20240144 A1 PE20240144 A1 PE 20240144A1
- Authority
- PE
- Peru
- Prior art keywords
- disorders
- nrcrd
- ora
- ring
- heteroaryl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163168407P | 2021-03-31 | 2021-03-31 | |
| US202263318118P | 2022-03-09 | 2022-03-09 | |
| PCT/US2022/022525 WO2022212489A1 (en) | 2021-03-31 | 2022-03-30 | Mk2 inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240144A1 true PE20240144A1 (es) | 2024-02-01 |
Family
ID=83459911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002765A PE20240144A1 (es) | 2021-03-31 | 2022-03-30 | Inhibidores de mk2 y usos de estos |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11680056B2 (enExample) |
| EP (1) | EP4313970A4 (enExample) |
| JP (1) | JP7887433B2 (enExample) |
| KR (1) | KR20230163501A (enExample) |
| AU (1) | AU2022252242A1 (enExample) |
| BR (1) | BR112023019861A2 (enExample) |
| CA (1) | CA3215746A1 (enExample) |
| CL (1) | CL2023002921A1 (enExample) |
| CO (1) | CO2023013150A2 (enExample) |
| CR (1) | CR20230468A (enExample) |
| DO (1) | DOP2023000212A (enExample) |
| IL (1) | IL307187A (enExample) |
| MX (1) | MX2023011503A (enExample) |
| PE (1) | PE20240144A1 (enExample) |
| TW (1) | TW202304879A (enExample) |
| WO (1) | WO2022212489A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022212489A1 (en) | 2021-03-31 | 2022-10-06 | Xinthera, Inc. | Mk2 inhibitors and uses thereof |
| US11685719B2 (en) | 2021-07-09 | 2023-06-27 | Xinthera, Inc. | Pyridinone MK2 inhibitors and uses thereof |
| CN116444492B (zh) * | 2021-12-29 | 2026-03-03 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| WO2023125708A1 (zh) * | 2021-12-29 | 2023-07-06 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN116396274B (zh) * | 2022-01-06 | 2025-11-11 | 深圳信立泰药业股份有限公司 | 一种取代的联吡啶酮类化合物及其制备方法与应用 |
| CN116425722B (zh) * | 2022-01-13 | 2025-11-11 | 深圳信立泰药业股份有限公司 | 一种取代的联吡啶酮-芳(杂)环类化合物及其制备方法与应用 |
| EP4464694A4 (en) * | 2022-01-14 | 2026-04-01 | Shanghai Hansoh Biomedical Co Ltd | POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE |
| CN116444493A (zh) * | 2022-01-14 | 2023-07-18 | 上海翰森生物医药科技有限公司 | 含双并环类衍生物、其制备方法和应用 |
| CN117800948A (zh) * | 2022-05-12 | 2024-04-02 | 上海美悦生物科技发展有限公司 | 取代的吡啶或嘧啶类衍生物及其药物组合物、制备方法和用途 |
| TW202412792A (zh) * | 2022-08-30 | 2024-04-01 | 大陸商長春金賽藥業有限責任公司 | ｐ３８α－ＭＫ２抑制劑化合物、藥物組合物及其用途 |
| US20240182449A1 (en) * | 2022-10-05 | 2024-06-06 | Xinthera, Inc. | Crystalline forms of an mk2 inhibitor |
| CN118047757A (zh) * | 2022-11-16 | 2024-05-17 | 上海美悦生物科技发展有限公司 | 吡啶氮氧化物类衍生物及其药物组合物、制备方法和用途 |
| US20260217652A1 (en) * | 2023-01-13 | 2026-07-30 | Shanghai Meiyue Biotech Development Co., Ltd. | Phenyl-substituted heteroaryl compound and pharmaceutical composition comprising same, preparation method therefor and use thereof |
| CN121368484A (zh) * | 2023-06-26 | 2026-01-20 | 深圳信立泰药业股份有限公司 | 一种mk2抑制剂在制备预防和/或治疗疾病药物中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP1822A (en) * | 2002-02-14 | 2008-01-30 | Pharmacia Corp | Substituted pyridinones as modulators of P38 MAP kinase. |
| US20070167621A1 (en) * | 2003-04-03 | 2007-07-19 | Pharmacia Corporation | Substituted pyrimidinones |
| US7183287B2 (en) * | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| CL2004002050A1 (es) * | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
| EP1987022A1 (en) * | 2006-02-10 | 2008-11-05 | Pfizer Products Inc. | Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives |
| JP2010529129A (ja) * | 2007-06-06 | 2010-08-26 | タイロジェネックス，インコーポレイテッド | キナーゼ阻害剤化合物 |
| EP2437598A4 (en) | 2009-06-03 | 2012-10-31 | Glaxosmithkline Llc | BIS-PYRIDYLPYRIDONES AS MELANGE-CONCENTRATION HORMONE RECEPTOR ANTAGONISTS |
| DK2648516T3 (da) * | 2010-12-06 | 2019-01-02 | Aclaris Therapeutics Inc | Substituerede pyridinon-pyridinylforbindelser |
| US9359300B2 (en) | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
| JP2014531425A (ja) | 2011-09-02 | 2014-11-27 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | 肥満の代謝異常を治療するためのＣａＭＫＩＩ、ＩＰ３Ｒ、カルシニューリン、ｐ３８、およびＭＫ２／３阻害剤 |
| US9056110B2 (en) * | 2011-12-06 | 2015-06-16 | Confluence Life Sciences, Inc. | Substituted pyrimidinone-phenyl-pyrimidinyl compounds |
| US9365540B2 (en) * | 2012-01-12 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Benzimidazole derivatives as MCH receptor antagonists |
| KR102313515B1 (ko) * | 2013-06-07 | 2021-10-14 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 메틸/플루오로-피리디닐-메톡시 치환된 피리디논-피리디닐 화합물 및 플루오로-피리미디닐-메톡시 치환된 피리디논-피리디닐 화합물 |
| CN114206339A (zh) | 2019-07-31 | 2022-03-18 | 阿克拉瑞斯治疗股份有限公司 | 氘化mk2途径抑制剂及其使用方法 |
| IL296054A (en) | 2020-03-27 | 2022-10-01 | Aclaris Therapeutics Inc | Oral compositions of mk2 pathway inhibitor for treatment of immune conditions |
| WO2022081573A1 (en) * | 2020-10-12 | 2022-04-21 | University Of Tennessee Research Foundation | Transient receptor potential canonical 3 inhibitors and methods of use thereof |
| KR20230112696A (ko) | 2020-11-23 | 2023-07-27 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피리디논-피리디닐 화합물의 합성 방법 |
| EP4284805A1 (en) | 2021-02-01 | 2023-12-06 | Celgene Corporation | Mk2 inhibitors, the synthesis thereof, and intermediates thereto |
| JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Ｇｐｒ８４アンタゴニストおよびその使用 |
| PY2222114A (es) | 2021-03-31 | 2023-01-19 | Syngenta Crop Protection Ag | Derivados microbiocidas de quinolin/quinoxalin-benzotiazina |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| US11780832B2 (en) | 2021-03-31 | 2023-10-10 | Fedora Pharmaceuticals Inc. | Lactivicin compounds, their preparation and use as antibacterial agents |
| WO2022212489A1 (en) | 2021-03-31 | 2022-10-06 | Xinthera, Inc. | Mk2 inhibitors and uses thereof |
| PE20250262A1 (es) | 2021-05-14 | 2025-01-29 | Bristol Myers Squibb Co | Compuestos heterociclicos sustituidos |
| US20230135894A1 (en) | 2021-06-30 | 2023-05-04 | Kymera Therapeutics, Inc. | Mk2 degraders and uses thereof |
| US11685719B2 (en) | 2021-07-09 | 2023-06-27 | Xinthera, Inc. | Pyridinone MK2 inhibitors and uses thereof |
| WO2023001282A1 (zh) | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 杂环取代的嘧啶衍生物 |
| TW202315625A (zh) | 2021-08-13 | 2023-04-16 | 大陸商深圳信立泰藥業股份有限公司 | 三聯吡啶二酮化合物或其鹽、包括其藥物組合物及其用途 |
| CN116178345B (zh) | 2021-10-19 | 2024-08-13 | 深圳信立泰药业股份有限公司 | 一种取代的嘧啶基-吡啶基-吡啶酮化合物及其制备方法与应用 |
| WO2023125708A1 (zh) | 2021-12-29 | 2023-07-06 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN116444492B (zh) | 2021-12-29 | 2026-03-03 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| CN115636814A (zh) | 2022-02-28 | 2023-01-24 | 瑞石生物医药有限公司 | 一种嘧啶衍生物及其用途 |
-
2022
- 2022-03-30 WO PCT/US2022/022525 patent/WO2022212489A1/en not_active Ceased
- 2022-03-30 BR BR112023019861A patent/BR112023019861A2/pt not_active Application Discontinuation
- 2022-03-30 CR CR20230468A patent/CR20230468A/es unknown
- 2022-03-30 JP JP2023560811A patent/JP7887433B2/ja active Active
- 2022-03-30 PE PE2023002765A patent/PE20240144A1/es unknown
- 2022-03-30 TW TW111112312A patent/TW202304879A/zh unknown
- 2022-03-30 MX MX2023011503A patent/MX2023011503A/es unknown
- 2022-03-30 EP EP22782084.2A patent/EP4313970A4/en active Pending
- 2022-03-30 AU AU2022252242A patent/AU2022252242A1/en active Pending
- 2022-03-30 KR KR1020237037138A patent/KR20230163501A/ko active Pending
- 2022-03-30 CA CA3215746A patent/CA3215746A1/en active Pending
- 2022-03-30 IL IL307187A patent/IL307187A/en unknown
- 2022-07-19 US US17/868,567 patent/US11680056B2/en active Active
-
2023
- 2023-05-02 US US18/310,943 patent/US12545662B2/en active Active
- 2023-07-13 US US18/352,078 patent/US11987574B2/en active Active
- 2023-09-29 DO DO2023000212A patent/DOP2023000212A/es unknown
- 2023-09-29 CL CL2023002921A patent/CL2023002921A1/es unknown
- 2023-10-02 CO CONC2023/0013150A patent/CO2023013150A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022252242A1 (en) | 2023-10-05 |
| EP4313970A1 (en) | 2024-02-07 |
| JP2024512154A (ja) | 2024-03-18 |
| JP7887433B2 (ja) | 2026-07-09 |
| MX2023011503A (es) | 2023-10-19 |
| US20230373969A1 (en) | 2023-11-23 |
| EP4313970A4 (en) | 2025-06-25 |
| KR20230163501A (ko) | 2023-11-30 |
| IL307187A (en) | 2023-11-01 |
| US20230265076A1 (en) | 2023-08-24 |
| CR20230468A (es) | 2023-12-07 |
| US12545662B2 (en) | 2026-02-10 |
| US20220402892A1 (en) | 2022-12-22 |
| TW202304879A (zh) | 2023-02-01 |
| US11987574B2 (en) | 2024-05-21 |
| DOP2023000212A (es) | 2023-11-30 |
| BR112023019861A2 (pt) | 2023-11-07 |
| CO2023013150A2 (es) | 2024-02-05 |
| US11680056B2 (en) | 2023-06-20 |
| WO2022212489A1 (en) | 2022-10-06 |
| CA3215746A1 (en) | 2022-10-06 |
| CL2023002921A1 (es) | 2024-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023013150A2 (es) | Inhibidores de mk2 y usos de estos | |
| CO5601020A2 (es) | Compuestos ox-azabiciclicos | |
| FR930186A (fr) | Procédé de purification de nitriles | |
| EP4118089C0 (en) | Crystallization of 2'-fl | |
| FR876891A (fr) | Poteau en béton armé et son procédé de montage et d'érection | |
| PE20060458A1 (es) | Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm y procedimiento para su preparacion | |
| EP4138837A4 (en) | TREATMENT OF AMYLOIDOSIS | |
| FR894362A (fr) | Schéma lumineux constitué par des unités assemblées comme éléments constructifs | |
| BR7100945D0 (pt) | Tratamento integrado de aguas residuarias para aplicacao apos banhos de cianato | |
| FR1270638A (fr) | Procédé d'amélioration du rendement des sources d'éclairage dites | |
| UY29158A1 (es) | Metodos de tratamiento de la epileptogénesis y la epilepsia | |
| SU9773A1 (ru) | Игольный микрофон | |
| FR1242945A (fr) | Procédé de fixation du culot des lampes d'éclairage | |
| FR1259729A (fr) | Procédé pour augmenter le rendement des fours siemens-martin | |
| FR52989E (fr) | Procédé d'épuration d'eaux résiduaires | |
| JP1722719S (ja) | 照明器具 | |
| FR85833E (fr) | Procédé de fixation du culot des lampes d'éclairage | |
| FR858847A (fr) | Procédé et dispositif pour augmenter le rendement des fours à cuve en particulier des hauts-fourneaux | |
| Roura-Parella | Wiese | |
| FR905401A (fr) | Application nouvelle d'un traitement thermique à la purification et l'enrichissement du sulfate de strontium naturel par l'élimination du carbonate de calcium | |
| FR878827A (fr) | Procédé de purification du chlorure de zinc | |
| FR701529A (fr) | Fabrication intensive du carbonate de magnésie léger et du carbonate de chaux léger et éventuellment de carbonate de potasse et de chlorure de magnésium au moyen dedolomie | |
| FR857028A (fr) | Procédé de fabrication de magnésie et de chaux en partant de la dolomie | |
| FR977749A (fr) | Complexe ferrique et son application au traitement des végétaux chlorotiques | |
| FR973653A (fr) | Utilisation des boues calcaires ammoniacales produites dans la fabrication du sulfate d'ammoniaque par le gypse |